Latest news with #PanOptix
Yahoo
15 hours ago
- Business
- Yahoo
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Clareon PanOptix Pro has half the light scatter of Clareon PanOptix1-3,*,** PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics1-4,*,**,† Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,††,‡ TORONTO, June 20, 2025--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics.1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.10-13,§,§§,¶,¶¶ "As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D," said Rob Scott, VP, Intraocular Devices, R&D, Alcon. "Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro.1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL."1-3,20,21,*,**,‡‡,‖,Ω "PanOptix has been a cornerstone of my cataract practice for eight years," said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. "These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile25, ∂and a happy patient with greater spectacle independence.23, § So, it's exciting to see this technology evolve to further meet patients' visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients." PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe® preloaded delivery system and as well as with the Clareon Monarch® IV delivery system in early 2026.22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering.22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative. About Clareon PanOptix Pro The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at *PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light). **Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner. †For feasible diffractive optics of up to pentafocal design from Krackhardt et al. ††Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic. ‡Compared to Clareon PanOptix. ‡‡Based on bench and vision simulator studies. §Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276). §§All-implanted analysis set. ¶In response to the IOLSAT questionnaire question "In the past 7 days, how often did you need to wear eyeglasses to see"? ¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127. ‖Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024. ΩSeverity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64). ∂Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including "very bothersome" and "severe" visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent. References Alcon data on file, 2025. REF-25218 Alcon data on file, 2024. REF-25221 Alcon data on file, 2015. REF-08546 Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston. Rayner Professional Website. Accessed September 2024. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; Accessed September 2024. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234. Alcon data on file, 2024. REF-23958. Alcon data on file, 2018. REF-01475. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965 Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164 Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/ Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/ Alcon data on file, 2024. REF-25903 Alcon data on file, 2024. REF-23554 MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023. Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use. Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/ Vision LLC. Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/ Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Connect with us onFacebook LinkedIn View source version on Contacts Media Relations Jane Lee Cheung+1 289 290 2393 (Canada) Sign in to access your portfolio
Business Wire
16 hours ago
- Business
- Business Wire
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon ® PanOptix ® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN ® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL. 1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics. 1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate. 1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix. 10-13,§,§§,¶,¶¶ "Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients.' Share 'As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,' said Rob Scott, VP, Intraocular Devices, R&D, Alcon. 'Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. 1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL.' 1-3,20,21,*,**,‡‡,‖,Ω 'PanOptix has been a cornerstone of my cataract practice for eight years,' said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. 'These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile 25, ∂ and a happy patient with greater spectacle independence. 23, § So, it's exciting to see this technology evolve to further meet patients' visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible ‡,‡‡, empowering both my practice and my patients.' PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe ® preloaded delivery system and as well as with the Clareon Monarch ® IV delivery system in early 2026. 22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering. 22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative. About Clareon PanOptix Pro The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at * PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light). ** Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner. † For feasible diffractive optics of up to pentafocal design from Krackhardt et al. †† Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic. ‡ Compared to Clareon PanOptix. ‡‡ Based on bench and vision simulator studies. §Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276). §§All-implanted analysis set. ¶In response to the IOLSAT questionnaire question 'In the past 7 days, how often did you need to wear eyeglasses to see'? ¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127. ‖ Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024. Ω Severity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64). ∂ Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including "very bothersome' and "severe" visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent. Expand References Alcon data on file, 2025. REF-25218 Alcon data on file, 2024. REF-25221 Alcon data on file, 2015. REF-08546 Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston. Rayner Professional Website. Accessed September 2024. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; Accessed September 2024. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234. Alcon data on file, 2024. REF-23958. Alcon data on file, 2018. REF-01475. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965 Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164 Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/ Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/ Alcon data on file, 2024. REF-25903 Alcon data on file, 2024. REF-23554 MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023. Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use. Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/ Vision LLC. Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/ Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.
Yahoo
04-04-2025
- Business
- Yahoo
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies have limited the ability to halt or reverse the damage, particularly caused by diseases such as age-related macular degeneration (AMD), glaucoma and retinitis pigmentosa. However, emerging cell and gene therapies hold the potential to change this landscape dramatically. The global cell-based ophthalmic therapies market was valued at $1.2 billion in 2023 and is projected to reach approximately $7.1 billion by 2032, exhibiting a CAGR of 21.3% during the forecast period. This growth is likely to be driven by advancements in biotechnology, an increasing prevalence of eye diseases and a growing demand for innovative treatments. This hugely promising market, while witnessing rapid advancements, is still in the early stages of development and the prospects are majorly untapped. Companies with a strong presence in the ophthalmic market, such as Alcon Inc. ALC, Glaukos Corporation GKOS and Regeneron Pharmaceuticals, Inc. REGN, are well-positioned to leverage this prospect, making them promising investment opportunities. Cell and Gene therapy, particularly using adeno-associated virus vectors, is showing promise in addressing inherited retinal diseases such as retinitis pigmentosa and Leber congenital amaurosis by delivering therapeutic genes directly to retinal cells. Meanwhile, regenerative medicine techniques, including stem cell therapy and tissue engineering, are opening new possibilities for restoring lost vision and repairing damaged ocular tissues. Technological innovations are also enhancing the space. AI-driven diagnostics and treatment planning are improving accuracy and efficiency, while advanced drug delivery systems, such as sustained-release implants and nanoparticle carriers, are enabling targeted therapy with fewer side effects. Additionally, the rise of telemedicine and remote monitoring through wearable devices is facilitating early detection and management of degenerative eye diseases, ensuring timely intervention and better patient outcomes. Alcon: Within its Surgical business, Alcon has been gaining market share, driven by strong consumables, implantable and equipment sales. Its flagship lenses, Vivity, PanOptix and several new launches, including Unity VCS, continue to lead the category globally. The Vision Care segment banks on the strength of contact lenses and ocular health products. The company has been witnessing strong uptake from its expanding product portfolios. To progress with cell therapy, the company recently acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Glaukos: This ophthalmic medical technology and pharmaceutical company is witnessing strong demand across international glaucoma and corneal health franchises. Moreover, the launch of iStent infinite has boosted the U.S. glaucoma franchise. The recent approval for iDose TR, a revolutionary micro-invasive, injectable therapy for glaucoma, will likely become another key product during 2025. The company commenced a phase 2b/3 clinical trial for its next-generation iDose therapy, iDose TREX, during the fourth quarter of 2024. Regeneron: This biotechnology company's portfolio includes Eylea (for several eye diseases), its key growth driver. Eylea is approved in the United States, the EU, Japan and other countries for the treatment of neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion. Regeneron received FDA approval for aflibercept 8 mg for the treatment of patients with wet AMD, DME and diabetic retinopathy under the brand name Eylea HD. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report Glaukos Corporation (GKOS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
02-04-2025
- Business
- Yahoo
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
Clareon PanOptix Pro provides unprecedented 94% light utilization, resulting in half the light scatter of Clareon PanOptix1,2,§,* Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,† Commercially available in the U.S. in May, Clareon PanOptix Pro is the next generation of the world's leading trifocal IOL3-5,‡ GENEVA, April 02, 2025--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in the U.S. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the highest reported light utilization of any trifocal IOL—and the lowest light scatter.1-3,6-10,§,** These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.1,† PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.1,2,11,12,**,°,Δ "As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix," said Rob Scott, VP, Intraocular Devices, R&D, Alcon. "Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro.1,2,13-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL."3-5,‡ "PanOptix has been a game-changer in my practice, allowing me to reliably offer many of my patients complete freedom from glasses after cataract surgery," said Kerry Solomon, MD, Medical Director at Carolina Eyecare Physicians, LLC.11,20 "I was excited to learn that Alcon evolved this leading technology for more light utilization and less light scatter.1,2,* My early patient results with PanOptix Pro support that this advancement builds on the well-established performance of PanOptix." PanOptix Pro will be the first presbyopia-correcting IOL available in the U.S. from Alcon in the single-use Clareon AutonoMe® preloaded delivery system. PanOptix Pro will also be available for use with the Clareon Monarch® IV delivery system beginning in 2026.12 PanOptix Pro offers powers ranging from +6.0 through +30.0 diopters (in 0.5 diopter increments), +31.0 through +34.0 diopters (in 1.0 diopter increments), with a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering.12 PanOptix Pro has been introduced to select practices across the U.S., with broad commercial availability in May. Additional markets will begin rollout in late 2025. For surgeons interested in more information on PanOptix Pro, visit or visit the Alcon Booth #1815 at the American Society of Cataract and Refractive Surgery annual meeting (Los Angeles, April 25-28). For patients interested in learning more about PanOptix Pro, visit About AlconAlcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at About Clareon PanOptix ProThe Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Potential Side Effects: Due to the design of multifocal IOLs, there are some side effects that can be associated with the Clareon PanOptix Pro Trifocal IOL models. These may be worse than with a monofocal IOL, including visual disturbances such as glare, rings around lights, starbursts (rays around light sources), and reduced contrast sensitivity (decreased ability to distinguish objects from their background, especially in dim lighting). These side effects may make it more difficult to see while driving at night or completing tasks in low lighting conditions such as at night or in fog or in a dimly lit room after surgery, as compared to before surgery. *Compared to Clareon PanOptix. PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro has 94% light utilization (6% scatter light).†Based on bench-measured, average white-light modular transfer function (MTF) from 0 to 70 lp/mm at 3mm aperture, compared to PanOptix.‡Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof® IQ PanOptix through Q1, 2024.§Based on manufacturer reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner.**Based on bench and vision simulator studies.°Based on data for AcrySof IQ PanOptix Trifocal IOL.ΔResponse to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127. References Alcon data on file, 2025. REF-25218 Alcon data on file, 2015. REF-08546 Alcon data on file, 2024. REF-25221 Alcon data on file, 2024. REF-23554 MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston. Rayner Professional Website. Accessed March 2025. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; Accessed March 2025. Zhu D, Ren S, Mills K, Hull J, Dhariwal M. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2): Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614-1617. doi:10.1177/154193120805201965. Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164. Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/ Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/ Alcon data on file, 2024. REF-25903 Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021. Connect with us onFacebook LinkedIn View source version on Contacts Investor Relations Daniel Cravens, Allen Trang+ 41 589 112 110 (Geneva)+ 1 817 615 2789 (Fort Worth) Media Relations Steven Smith+ 41 589 112 111 (Geneva)+ 1 817 551 8057 (Fort Worth) Sign in to access your portfolio
